Protocol Ledger

NCT07020065 · Phase II · RECRUITING

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Interventional Phase II clinical trial protocol NCT07020065 sponsored by Swiss Cancer Institute in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-10 Enrollment: 156 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07020065
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)156 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07020065
Protocol FieldVerified Registry Value
NCT IdentifierNCT07020065
Consolidated Lead SponsorSwiss Cancer Institute
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment156 participants (ESTIMATED)
Registered Start Date2026-04-10
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI